Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
Iran says to oversee Hormuz as Swiss talks conclude
-
Diaspora World Cup champions diversity over division
-
Guns, drones and doves: War reshapes Ukrainian jewellery scene
-
Australia withholds Pacific climate fund reports over risk of diplomatic 'damage'
-
Kenya police violence victims say compensation promise a 'smokescreen'
-
Indian startup head appointed as new WhatsApp boss
-
EU bets on digital euro to cut US tech addiction
-
Antetokounmpo joining Miami Heat in blockbuster: reports
-
Fineanganofo rethinks Newcastle move after All Blacks call-up
-
'Let's be realistic': Haaland cools Norway's World Cup expectations
-
Stocks fluctuate after Wall St sell-off, crude holds losses on peace talks
-
Lightning, downpour, a two-hour delay: bad weather hits the World Cup
-
Ultra-reclusive Turkmenistan slowly opens up to tourists
-
Two-goal Haaland fires Norway into World Cup last 32
-
Marc Bloch, historian and Resistance hero, joins France's Pantheon greats
-
Last one the best one? How Messi keeps doing it at World Cup
-
Ronaldo 'a role model' says Portugal coach after slow World Cup start
-
Savea 'embraces challenge' of leading All Blacks towards World Cup
-
North Korea's Kim vows to accelerate military buildup
-
Savea 'embraces challlenge' of leading All Blacks towards World Cup
-
Latin America's resurgent right notches another win in Colombia
-
Mbappe scores twice as France beat Iraq at World Cup after two-hour storm delay
-
Trump threatens prison for damage to Washington Reflecting Pool
-
France-Iraq World Cup game restarts after two-hour storm delay
-
Shortages ease in Bolivia as protest roadblocks dismantled
-
World Cup exploits of Maradona and Messi have Argentina fans in raptures
-
North America LiberNovo Prime Sale Fully Launches June 23
-
Empire Metals Limited Announces Investor Presentation on Investor Meet Company
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 23
-
Who Is Really Influencing Trump Marijuana Rescheduling?
-
CTO Confidence in Scaling AI Falls for Third Straight Year, Akkodis Report Finds
-
Star Copper Extends Copper Creek Drill Hole Beyond Planned Depth After Intersecting Mineralized System
-
England 'can beat any opponent' at World Cup, says Rice
-
'Boston Tea Party' compensation claim to be displayed at UK exhibit
-
Alvarez says 'best for everyone' if he leaves Atletico
-
France-Iraq World Cup game suspended due to severe weather alert
-
Romanian parliament rejects liberal PM-designate
-
US temporarily suspends Iran oil sanctions, says nuclear inspectors to return
-
Maduro ouster put Venezuela on 'the right path': interim leader
-
Missed penalty spurred 'very angry' Messi to World Cup history
-
Shooting in Montreal, Canada leaves three dead including suspect
-
Oil falls as US waives Iranian sanctions and Nasdaq tumbles
-
Balogun chases 'inevitable' Messi in wild Golden Boot race
-
Defeated Colombian leftist calls for calm after post-vote violence
-
Belgium's Doku becomes father after World Cup controversy
-
Messi sets World Cup scoring record as Argentina down Austria
-
Magic Messi makes World Cup history to send Argentina into last 32
-
French TV presenter stood down over Doku World Cup comments
-
Ghana coach Queiroz says playing England 'easiest' World Cup game
-
Messi sets World Cup scoring record with 17th goal
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
T.Perez--AT